The U.S. Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to TTX101 for use in patients with malignant gliomas.
The U.S. Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to TTX101 for use in patients with malignant gliomas.
AI and Quantitative image analysis will help to identify early treatment changes in GBM patients and support the development of predictive response markers.
The start-up TargTex and the pharmaceutical company Basi close a seed-extension investment
These awards are attributed by Exame Informática …
Researchers form the Instituto de Medicina Molecular have created an artificial intelligence platform …